Adaptive Vaccination Solutions for Specialized Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts the original peptides derived from Acinetobacter baumannii for vaccination in specialized environments, such as high-security facilities, disaster relief areas, extreme weather conditions, high-altitude environments, and high-stress environments.
Background and Problem Solved
The original patent relates to novel proteins and polynucleotides derived from Acinetobacter baumannii for antimicrobial prophylaxis and therapy. However, these compositions may not be suitable for specific, narrow markets or unique operational environments. The present inventive concept addresses this limitation by adapting the peptides for use in specialized environments, providing targeted solutions for these niche markets.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system, method, or portable kit for vaccination in specialized environments, utilizing peptides derived from Acinetobacter baumannii with a sequence identity of at least 90% to SEQ ID NO: 27. These solutions are adapted for use in high-security facilities, disaster relief areas, extreme weather conditions, high-altitude environments, and high-stress environments, ensuring effective vaccination in these unique contexts.
Novelty and Inventive Step
The new claims introduce novel and non-obvious adaptations of the original peptides for vaccination in specialized environments, which are not anticipated by the original patent. The inventive step lies in the specific combinations of peptides, adjuvants, and carriers tailored to these niche markets, providing a unique value proposition for users in these environments.
Alternative Embodiments and Variations
Alternative embodiments may include varying the sequence identity of the peptides, using different adjuvants or carriers, or incorporating additional components to enhance the vaccination process. Variations may also include adapting the solutions for use in other specialized environments, such as space exploration or remote communities.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, targeting niche markets such as high-security facilities, disaster relief organizations, and extreme weather condition responders. The solutions may also be applicable to other industries, such as aerospace or remote community healthcare, providing a broad market opportunity.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/104 |
| C | C07 | C07K14/212 |
| A | A61 | A61K2039/543 |
| A | A61 | A61K2039/55505 |
| A | A61 | A61K2039/55566 |
| G | G01 | G01N2333/22 |
| G | G01 | G01N2469/20 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and immunological vaccine development, specifically focused on peptide-based vaccines for microbial prophylaxis, with expertise in protein engineering, immunological adjuvant formulation, and adaptive vaccine design
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in microbiology or immunology, experienced in protein sequence analysis, vaccine development techniques, and understanding of peptide modification strategies, familiar with computational tools for sequence comparison and vaccine optimization
Obviousness Rationale
A person skilled in the art would recognize that adapting the Acinetobacter baumannii peptide vaccine for specialized environments represents a predictable variation of the original patent's core technology. The fundamental vaccine composition remains substantially unchanged, with only contextual modifications that a skilled practitioner would consider routine engineering adaptations. The variations demonstrate standard design choices in vaccine development, leveraging known techniques for tailoring immunological compositions to specific use cases.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,615 |
|---|---|
| Title | Peptides derived from Acinetobacter baumannii and their use in vaccination |
| Assignee(s) | Evaxion Biotech A/S |